Terasaki Institute for Biomedical Innovation Welcomes New Member to Leadership Board

March 23, 2022

– The Terasaki Institute for Biomedical Innovation (TIBI) is pleased to announce the addition of Nazli Azimi, Pharm.D., Ph.D., to its Leadership Board. Until its recent acquisition by Equillium Inc, Dr. Azimi was the Founder and Chief Executive Officer of Bioniz Therapeutics, Inc., and co-inventor of its platform technology that was focused on developing novel therapies for treating immune system diseases and cancer.

Terasaki Institute For Biomedical Innovation is Awarded Grant From METAvivor

February 21, 2022

– Vadim Jucaud, Ph.D., Assistant Professor at the Terasaki Institute for Biomedical Innovation (TIBI), has been awarded an Early Career Investigator grant from METAvivor. This volunteer-led, non-profit organization supports vital research to benefit stage IV metastatic breast cancer (mBC) patients. METAvivor is dedicated to improving the longevity and quality of life of these patients and is the only organization in the United States that annually funds this type of research. The grant will fund a project titled

“Microengineered Approach to Develop Personalized Monoclonal Antibodies for Metastatic Breast Cancer Treatment.”

TIBI Innovation- Biomedical Grand Challenges

February 20, 2022

– In 1900, David Hilbert, a German Mathematician, developed a list of “mathematical problems” that had gone unsolved. He presented this list to an international society of mathematicians, which created a focus on the energy, time, and funding to solve these problems. In essence, the concept of Grand Challenges was born.

TumSince then, this idea of catalyzing communities of researchers to focus on the most challenging problems facing their respective fields has blossomed on an international scale. Nearly every foundation, academic institution, government, and even some private industry groups have used the Grand Challenges process to stimulate new ideas and galvanize their members to focus on these intractable issues.

Genetic Remodeling in Tumor Formation

Scientists delineate process which drives tumor formation by Kras oncogenes

February 8, 2022

– Cancerous tumors are made up of rapidly growing, abnormally shaped, cells that can infiltrate and destroy healthy tissues, travel to other parts of the body, and form additional tumors. In part because of its rapid and invasive nature, cancer remains the second leading cause of death in the United States and a major cause of death worldwide.

Tumor formation is often driven by genes called oncogenes, which are usually involved in the normal processes of cell growth, proliferation, and death. But they can also mutate and be expressed at high levels, which can drive the multiplication of cancerous cells.

Terasaki Institute for Biomedical Innovation Announces Partnership with Rousselot

January 12, 2022

– The Terasaki Institute for Biomedical Innovation (TIBI), a non-profit multidisciplinary bioengineering research institution, announces their partnership with Darling Ingredients’ health brand, Rousselot®, the world leader in collagen-based solutions, with more than 130 years of gelatin and collagen expertise.

With their long-standing experience in tissue engineering and regeneration, bio-fabrication using 3D printing and engineering micro- and nano-scale medical devices, TIBI has relied heavily on the use of modified and functionalized gelatin biomaterials for their research and experimentation. In doing so, they have developed valuable insights into gelatin’s behavior and have used this knowledge to optimize and tune gelatin biomaterials for various biomedical applications.

Decreasing Cancer Drugs’ Side Effects

Scientists develop plant-based “hairy nanocrystals” to remove excess chemotherapy drugs from the blood

January 6, 2022

– Millions of people around the globe are affected by cancer each year; more than 39% of men and women are diagnosed with cancer during their lifetime. Chemotherapy is the most commonly employed, standard cancer treatment and targeted delivery of these drugs to the tumor site increases their effectiveness. However, excess drugs may still circulate to the rest of the body and cause multiple side effects, including anemia, chronic infections, hair loss, jaundice and fever.

Terasaki Institute for Biomedical Innovation  Year in Review 2021

December 16, 2021

(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI) has had a busy and productive year and has grown in many ways.

On the leadership side, TIBI is proud to welcome its new Chief Scientific Officer, Xiling Shen, Ph.D. Dr Shen is a highly accomplished scientist whose works span the multidisciplinary fields of biomedical engineering, computational techniques, cancer biology, and multi-omics methodology.